Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity

Frontiers in Bioscience

Volumn 16, Issue 9, 2011, Pages 3224-3232

  Strobl, Birgit ^a   Stoiber, Dagmar ^b,c   Sexl, Veronika ^a   Mueller, Mathias ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; Immunity; Infection; Janus kinase; Review; Signalling; TYK2

Indexed keywords

MUS;

EID: 84860281015     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3908     Document Type: Article

References (180)

1. Firmbach-Kraft, I., M. Byers, T. Shows, R. Dalla-Favera and J. J. Krolewski: tyk2, prototype of a novel class of nonreceptor tyrosine kinase genes. Oncogene, 5(9), 1329-36 (1990)
2. Krolewski, J. J., R. Lee, R. Eddy, T. B. Shows and R. Dalla-Favera: Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene, 5(3), 277-82 (1990)
3. Velazquez, L., M. Fellous, G. R. Stark and S. Pellegrini: A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell, 70(2), 313-22 (1992)
4. Darnell, J. E., Jr., I. M. Kerr and G. R. Stark: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264(5164), 1415-21 (1994) (Pubitemid 24217131)
5. Levy, D. E. and J. E. Darnell, Jr.: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol, 3(9), 651-62 (2002) (Pubitemid 34987786)
6. Ghoreschi, K., A. Laurence and J. J. O'Shea: Janus kinases in immune cell signaling. Immunol Rev, 228(1), 273-87 (2009)
7. Karaghiosoff, M., H. Neubauer, C. Lassnig, P. Kovarik, H. Schindler, H. Pircher, B. Mccoy, C. Bogdan, T. Decker, G. Brem, K. Pfeffer and M. Muller: Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity, 13(4), 549-60 (2000)
8. Shimoda, K., K. Kato, K. Aoki, T. Matsuda, A. Miyamoto, M. Shibamori, M. Yamashita, A. Numata, K. Takase, S. Kobayashi, S. Shibata, Y. Asano, H. Gondo, K. Sekiguchi, K. Nakayama, T. Nakayama, T. Okamura, S. Okamura and Y. Niho: Tyk2 plays a restricted role in IFNalpha signaling, although it is required for IL-12-mediated T cell function. Immunity, 13(4), 561-71 (2000)
9. Sheehan, K. C., K. S. Lai, G. P. Dunn, A. T. Bruce, M. S. Diamond, J. D. Heutel, C. Dungo-Arthur, J. A. Carrero, J. M. White, P. J. Hertzog and R. D. Schreiber: Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res, 26(11), 804-19 (2006) (Pubitemid 44764543)
10. Shaw, M. H., V. Boyartchuk, S. Wong, M. Karaghiosoff, J. Ragimbeau, S. Pellegrini, M. Muller, W. F. Dietrich and G. S. Yap: A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci U S A, 100(20), 11594-9 (2003) (Pubitemid 37205981)
11. Bieber, A. J., K. Suwansrinon, J. Kerkvliet, W. Zhang, L. R. Pease and M. Rodriguez: Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair. Proc Natl Acad Sci U S A, 107(2), 792-7 (2010)
12. Neubauer, H., A. Cumano, M. Muller, H. Wu, U. Huffstadt and K. Pfeffer: Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell, 93(3), 397-409 (1998) (Pubitemid 28232084)
13. Rodig, S. J., M. A. Meraz, J. M. White, P. A. Lampe, J. K. Riley, C. D. Arthur, K. L. King, K. C. Sheehan, L. Yin, D. Pennica, E. M. Johnson, Jr. and R. D. Schreiber: Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell, 93(3), 373-83 (1998) (Pubitemid 28232082)
14. Thomis, D. C., C. B. Gurniak, E. Tivol, A. H. Sharpe and L. J. Berg: Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science, 270(5237), 794-7 (1995)
15. Nosaka, T., J.M.A. van Deursen, R.A. Tripp, W.E. Thierfelder, B.A. Witthuhn, A.P. McMickle, P.C. Doherty, G.C. Grosveld, J.N. Ihle: Defective lymphoid development in mice lacking Jak3. Science, 270(5237), 800-802 (1995)
16. Gauzzi, M. C., L. Velazquez, R. Mckendry, K. E. Mogensen, M. Fellous and S. Pellegrini: Interferon-alphadependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J Biol Chem, 271(34), 20494-500 (1996) (Pubitemid 26281822)
17. Velazquez, L., K. E. Mogensen, G. Barbieri, M. Fellous, G. Uze and S. Pellegrini: Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction. J Biol Chem, 270(7), 3327-34 (1995)
18. Yeh, T. C., E. Dondi, G. Uze and S. Pellegrini: A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc Natl Acad Sci U S A, 97(16), 8991-6 (2000) (Pubitemid 30626661)
19. Staerk, J., A. Kallin, J. B. Demoulin, W. Vainchenker and S. N. Constantinescu: JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: crosstalk with IGF1 receptor. J Biol Chem, 280(51), 41893-9 (2005) (Pubitemid 43023158)
20. Gakovic, M., J. Ragimbeau, V. Francois, S. N. Constantinescu and S. Pellegrini: The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor. J Biol Chem, 283(27), 18522-9 (2008)
21. Richter, M. F., G. Dumenil, G. Uze, M. Fellous and S. Pellegrini: Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1. J Biol Chem, 273(38), 24723-9 (1998) (Pubitemid 28454973)
22. Daub, H., J. V. Olsen, M. Bairlein, F. Gnad, F. S. Oppermann, R. Korner, Z. Greff, G. Keri, O. Stemmann and M. Mann: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell, 31(3), 438-48 (2008)
23. Heibeck, T. H., S. J. Ding, L. K. Opresko, R. Zhao, A. A. Schepmoes, F. Yang, A. V. Tolmachev, M. E. Monroe, D. G. Camp, 2nd, R. D. Smith, H. S. Wiley and W. J. Qian: An extensive survey of tyrosine phosphorylation revealing new sites in human mammary epithelial cells. J Proteome Res, 8(8), 3852-61 (2009)
24. Oppermann, F. S., F. Gnad, J. V. Olsen, R. Hornberger, Z. Greff, G. Keri, M. Mann and H. Daub: Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics, 8(7), 1751-64 (2009)
25. Rikova, K., A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, J. Nardone, K. Lee, C. Reeves, Y. Li, Y. Hu, Z. Tan, M. Stokes, L. Sullivan, J. Mitchell, R. Wetzel, J. Macneill, J. M. Ren, J. Yuan, C. E. Bakalarski, J. Villen, J. M. Kornhauser, B. Smith, D. Li, X. Zhou, S. P. Gygi, T. L. Gu, R. D. Polakiewicz, J. Rush and M. J. Comb: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 131(6), 1190-203 (2007) (Pubitemid 350235027)
26. Zheng, H., P. Hu, D. F. Quinn and Y. K. Wang: Phosphotyrosine proteomic study of interferon alpha signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography. Mol Cell Proteomics, 4(6), 721-30 (2005) (Pubitemid 40879601)
27. Lucet, I. S., E. Fantino, M. Styles, R. Bamert, O. Patel, S. E. Broughton, M. Walter, C. J. Burns, H. Treutlein, A. F. Wilks and J. Rossjohn: The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood, 107(1), 176-83 (2006) (Pubitemid 43053540)
28. Boggon, T. J., Y. Li, P. W. Manley and M. J. Eck: Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood, 106(3), 996-1002 (2005) (Pubitemid 41076445)
29. Chrencik, J. E., A. Patny, I. K. Leung, B. Korniski, T. L. Emmons, T. Hall, R. A. Weinberg, J. A. Gormley, J. M. Williams, J. E. Day, J. L. Hirsch, J. R. Kiefer, J. W. Leone, H. D. Fischer, C. D. Sommers, H. C. Huang, E. J. Jacobsen, R. E. Tenbrink, A. G. Tomasselli and T. E. Benson: Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol, 400(3), 413-33 (2010)
30. Williams, N. K., R. S. Bamert, O. Patel, C. Wang, P. M. Walden, A. F. Wilks, E. Fantino, J. Rossjohn and I. S. Lucet: Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol, 387(1), 219-32 (2009)
31. Lindauer, K., T. Loerting, K. R. Liedl and R. T. Kroemer: Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng, 14(1), 27-37 (2001) (Pubitemid 32318935)
32. Giordanetto, F. and R. T. Kroemer: Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng, 15(9), 727-37 (2002) (Pubitemid 35470429)
33. Xu, D. and C. K. Qu: Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci, 13, 4925-32 (2008) (Pubitemid 351599646)
34. Tabrizi, M., W. Yang, H. Jiao, E. M. Devries, L. C. Platanias, M. Arico and T. Yi: Reduced Tyk2/SHP-1 interaction and lack of SHP-1 mutation in a kindred of familial hemophagocytic lymphohistiocytosis. Leukemia, 12(2), 200-6 (1998) (Pubitemid 28108072)
35. Yetter, A., S. Uddin, J. J. Krolewski, H. Jiao, T. Yi and L. C. Platanias: Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J Biol Chem, 270(31), 18179-82 (1995)
36. Wu, C., Q. Guan, Y. Wang, Z. J. Zhao and G. W. Zhou: SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J Cell Biochem, 90(5), 1026-37 (2003) (Pubitemid 37467118)
37. Myers, M. P., J. N. Andersen, A. Cheng, M. L. Tremblay, C. M. Horvath, J. P. Parisien, A. Salmeen, D. Barford and N. K. Tonks: TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem, 276(51), 47771-4 (2001)
38. Irie-Sasaki, J., T. Sasaki, W. Matsumoto, A. Opavsky, M. Cheng, G. Welstead, E. Griffiths, C. Krawczyk, C. D. Richardson, K. Aitken, N. Iscove, G. Koretzky, P. Johnson, P. Liu, D. M. Rothstein and J. M. Penninger: CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature, 409(6818), 349-54 (2001) (Pubitemid 32151240)
39. Croker, B. A., H. Kiu and S. E. Nicholson: SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol, 19(4), 414-22 (2008)
40. Narazaki, M., M. Fujimoto, T. Matsumoto, Y. Morita, H. Saito, T. Kajita, K. Yoshizaki, T. Naka and T. Kishimoto: Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci U S A, 95(22), 13130-4 (1998) (Pubitemid 28509536)
41. Sakamoto, H., H. Yasukawa, M. Masuhara, S. Tanimura, A. Sasaki, K. Yuge, M. Ohtsubo, A. Ohtsuka, T. Fujita, T. Ohta, Y. Furukawa, S. Iwase, H. Yamada and A. Yoshimura: A Janus kinase inhibitor, JAB, is an interferongamma-inducible gene and confers resistance to interferons. Blood, 92(5), 1668-76 (1998) (Pubitemid 28406871)
42. Zeng, B., H. Li, Y. Liu, Z. Zhang, Y. Zhang and R. Yang: Tumor-induced suppressor of cytokine signaling 3 inhibits toll-like receptor 3 signaling in dendritic cells via binding to tyrosine kinase 2. Cancer Res, 68(13), 5397-404 (2008)
43. Li, S., S. Labrecque, M. C. Gauzzi, A. R. Cuddihy, A. H. Wong, S. Pellegrini, G. J. Matlashewski and A. E. Koromilas: The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene, 18(42), 5727-37 (1999) (Pubitemid 29507426)
44. Geiger, T. R. and J. M. Martin: The Epstein-Barr virusencoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells. J Virol, 80(23), 11638-50 (2006) (Pubitemid 44788878)
45. Pugnale, P., V. Pazienza, K. Guilloux and F. Negro: Hepatitis delta virus inhibits alpha interferon signaling. Hepatology, 49(2), 398-406 (2009)
46. Komatsu, T., K. Takeuchi, J. Yokoo, Y. Tanaka and B. Gotoh: Sendai virus blocks alpha interferon signaling to signal transducers and activators of transcription. J Virol, 74(5), 2477-80 (2000) (Pubitemid 30091508)
47. Pestka, S., C. D. Krause and M. R. Walter: Interferons, interferon-like cytokines, and their receptors. Immunol Rev, 202, 8-32 (2004) (Pubitemid 39576902)
48. Chen, J., E. Baig and E. N. Fish: Diversity and relatedness among the type I interferons. J Interferon Cytokine Res, 24(12), 687-98 (2004) (Pubitemid 39658232)
49. Schindler, C. and C. Plumlee: Inteferons pen the JAKSTAT pathway. Semin Cell Dev Biol, 19(4), 311-8 (2008)
50. Van Boxel-Dezaire, A. H., M. R. Rani and G. R. Stark: Complex modulation of cell type-specific signaling in response to type I interferons. Immunity, 25(3), 361-72 (2006) (Pubitemid 44354225)
51. Gauzzi, M. C., G. Barbieri, M. F. Richter, G. Uze, L. Ling, M. Fellous and S. Pellegrini: The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proc Natl Acad Sci U S A, 94(22), 11839-44 (1997) (Pubitemid 27467804)
52. Ragimbeau, J., E. Dondi, A. Alcover, P. Eid, G. Uze and S. Pellegrini: The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J, 22(3), 537-47 (2003) (Pubitemid 36193598)
53. Kumar, K. G., B. Varghese, A. Banerjee, D. P. Baker, S. N. Constantinescu, S. Pellegrini and S. Y. Fuchs: Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif. J Biol Chem, 283(27), 18566-72 (2008)
54. Marijanovic, Z., J. Ragimbeau, K. G. Kumar, S. Y. Fuchs and S. Pellegrini: TYK2 activity promotes ligandinduced IFNAR1 proteolysis. Biochem J, 397(1), 31-8 (2006) (Pubitemid 44032833)
55. Rani, M. R., D. W. Leaman, Y. Han, S. Leung, E. Croze, E. N. Fish, A. Wolfman and R. M. Ransohoff: Catalytically active TYK2 is essential for interferon-betamediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem, 274(45), 32507-11 (1999)
56. Rani, M. R., C. Gauzzi, S. Pellegrini, E. N. Fish, T. Wei and R. M. Ransohoff: Induction of beta-R1/I-TAC by interferon-beta requires catalytically active TYK2. J Biol Chem, 274(4), 1891-7 (1999)
57. Rani, M. R., S. Pandalai, J. Shrock, A. Almasan and R. M. Ransohoff: Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta. J Interferon Cytokine Res, 27(9), 767-79 (2007) (Pubitemid 47479861)
58. Fish, E. N., S. Uddin, M. Korkmaz, B. Majchrzak, B. J. Druker and L. C. Platanias: Activation of a CrkL-stat5 signaling complex by type I interferons. J Biol Chem, 274(2), 571-3 (1999)
59. Hoyt, R., W. Zhu, F. Cerignoli, A. Alonso, T. Mustelin and M. David: Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase. J Immunol, 179(6), 3402-6 (2007)
60. Platanias, L. C. Mechanisms of type-I-and type-IIinterferon-mediated signalling. Nat Rev Immunol, 5(5), 375-86 (2005)
61. Yang, C. H., A. Murti, W. J. Valentine, Z. Du and L. M. Pfeffer: Interferon alpha activates NF-kappaB in JAK1-deficient cells through a TYK2-dependent pathway. J Biol Chem, 280(27), 25849-53 (2005) (Pubitemid 40962295)
62. Su, Q., S. Wang, D. Baltzis, L. K. Qu, J. F. Raven, S. Li, A. H. Wong and A. E. Koromilas: Interferons induce tyrosine phosphorylation of the eIF2alpha kinase PKR through activation of Jak1 and Tyk2. EMBO Rep, 8(3), 265-70 (2007) (Pubitemid 46344592)
63. Shaw, M. H., G. J. Freeman, M. F. Scott, B. A. Fox, D. J. Bzik, Y. Belkaid and G. S. Yap: Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. J Immunol, 176(12), 7263-71 (2006) (Pubitemid 43849026)
64. Commins, S., J. W. Steinke and L. Borish: The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol, 121(5), 1108-11 (2008)
65. Uze, G. and D. Monneron: IL-28 and IL-29: newcomers to the interferon family. Biochimie, 89(6-7), 729-34 (2007) (Pubitemid 47001631)
66. Watford, W. T., B. D. Hissong, J. H. Bream, Y. Kanno, L. Muul and J. J. O'Shea: Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev, 202, 139-56 (2004) (Pubitemid 39576910)
67. Shimoda, K., H. Tsutsui, K. Aoki, K. Kato, T. Matsuda, A. Numata, K. Takase, T. Yamamoto, H. Nukina, T. Hoshino, Y. Asano, H. Gondo, T. Okamura, S. Okamura, K. Nakayama, K. Nakanishi, Y. Niho and M. Harada: Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood, 99(6), 2094-9 (2002) (Pubitemid 34525493)
68. Tokumasa, N., A. Suto, S. Kagami, S. Furuta, K. Hirose, N. Watanabe, Y. Saito, K. Shimoda, I. Iwamoto and H. Nakajima: Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood, 110(2), 553-60 (2007) (Pubitemid 47105393)
69. Ortmann, R., R. Smeltz, G. Yap, A. Sher and E. M. Shevach: A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis. J Immunol, 166(9), 5712-9 (2001) (Pubitemid 32374196)
70. Schleicher, U., J. Mattner, M. Blos, H. Schindler, M. Rollinghoff, M. Karaghiosoff, M. Muller, G. Werner-Felmayer and C. Bogdan: Control of Leishmania major in the absence of Tyk2 kinase. Eur J Immunol, 34(2), 519-29 (2004) (Pubitemid 39255962)
71. Parham, C., M. Chirica, J. Timans, E. Vaisberg, M. Travis, J. Cheung, S. Pflanz, R. Zhang, K. P. Singh, F. Vega, W. To, J. Wagner, A. M. O'Farrell, T. Mcclanahan, S. Zurawski, C. Hannum, D. Gorman, D. M. Rennick, R. A. Kastelein, R. De Waal Malefyt and K. W. Moore: A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol, 168(11), 5699-708 (2002) (Pubitemid 34556153)
72. Nakamura, R., K. Shibata, H. Yamada, K. Shimoda, K. Nakayama and Y. Yoshikai: Tyk2-signaling plays an important role in host defense against Escherichia coli through IL-23-induced IL-17 production by gammadelta T cells. J Immunol, 181(3), 2071-5 (2008)
73. Oyamada, A., H. Ikebe, M. Itsumi, H. Saiwai, S. Okada, K. Shimoda, Y. Iwakura, K. I. Nakayama, Y. Iwamoto, Y. Yoshikai and H. Yamada: Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J Immunol, 183(11), 7539-46 (2009)
74. Hershey, G. K.: IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol, 111(4), 677-90 (2003) (Pubitemid 36470232)
75. Roy, B., A. Bhattacharjee, B. Xu, D. Ford, A. L. Maizel and M. K. Cathcart: IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats. J Leukoc Biol, 72(3), 580-9 (2002)
76. Roy, B. and M. K. Cathcart: Induction of 15-lipoxygenase expression by IL-13 requires tyrosine phosphorylation of Jak2 and Tyk2 in human monocytes. J Biol Chem, 273(48), 32023-9 (1998) (Pubitemid 29177143)
77. Bhattacharjee, A., A. Mulya, S. Pal, B. Roy, G. M. Feldman and M. K. Cathcart: Monocyte 15-lipoxygenase gene expression requires ERK1/2 MAPK activity. J Immunol, 185(9), 5211-24 (2010)
78. Yang, J. and G. R. Stark: Roles of unphosphorylated STATs in signaling. Cell Res, 18(4), 443-51 (2008) (Pubitemid 351498851)
79. Dinarello, C. A. and G. Fantuzzi: Interleukin-18 and host defense against infection. J Infect Dis, 187 Suppl 2, S370-84 (2003) (Pubitemid 36724511)
80. Stahl, N., T. G. Boulton, T. Farruggella, N. Y. Ip, S. Davis, B. A. Witthuhn, F. W. Quelle, O. Silvennoinen, G. Barbieri, S. Pellegrini, J. N. Ihle and G. D. Yancopoulos: Association and activation of Jak-Tyk kinases by CNTFLIF-OSM-IL-6 beta receptor components. Science, 263(5143), 92-5 (1994) (Pubitemid 24076263)
81. Chung, B. M., H. C. Kang, S. Y. Han, H. S. Heo, J. J. Lee, J. Jeon, J. Y. Lim, I. Shin, S. H. Hong, Y. S. Cho and C. G. Kim: Jak2 and Tyk2 are necessary for lineagespecific differentiation, but not for the maintenance of selfrenewal of mouse embryonic stem cells. Biochem Biophys Res Commun, 351(3), 682-8 (2006) (Pubitemid 44780857)
82. Shimoda, K., J. Feng, H. Murakami, S. Nagata, D. Watling, N. C. Rogers, G. R. Stark, I. M. Kerr and J. N. Ihle: Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor. Blood, 90(2), 597-604 (1997) (Pubitemid 27299099)
83. Marino, V. J. and L. P. Roguin: The granulocyte colony stimulating factor (G-CSF) activates Jak/STAT and MAPK pathways in a trophoblastic cell line. J Cell Biochem, 103(5), 1512-23 (2008) (Pubitemid 351490719)
84. Ezumi, Y., H. Takayama and M. Okuma: Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett, 374(1), 48-52 (1995)
85. Sattler, M., M. A. Durstin, D. A. Frank, K. Okuda, K. Kaushansky, R. Salgia and J. D. Griffin: The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol, 23(9), 1040-8 (1995)
86. Royer, Y., J. Staerk, M. Costuleanu, P. J. Courtoy and S. N. Constantinescu: Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem, 280(29), 27251-61 (2005) (Pubitemid 41040765)
87. Drachman, J. G., K. M. Millett and K. Kaushansky: Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem, 274(19), 13480-4 (1999)
88. Shimoda, K., K. Kamesaki, A. Numata, K. Aoki, T. Matsuda, K. Oritani, S. Tamiya, K. Kato, K. Takase, R. Imamura, T. Yamamoto, T. Miyamoto, K. Nagafuji, H. Gondo, S. Nagafuchi, K. Nakayama and M. Harada: Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation. J Immunol, 169(9), 4707-11 (2002) (Pubitemid 35217130)
89. Gamero, A. M., R. Potla, J. Wegrzyn, M. Szelag, A. E. Edling, K. Shimoda, D. C. Link, J. Dulak, D. P. Baker, Y. Tanabe, J. M. Grayson and A. C. Larner: Activation of Tyk2 and Stat3 is required for the apoptotic actions of interferon-beta in primary pro-B cells. J Biol Chem, 281(24), 16238-44 (2006)
90. Aoki, K., K. Shimoda, K. Oritani, T. Matsuda, K. Kamezaki, R. Muromoto, A. Numata, S. Tamiya, T. Haro, F. Ishikawa, K. Takase, T. Yamamoto, T. Yumioka, T. Miyamoto, K. Nagafuji, H. Gondo, S. Nagafuchi, K. Nakayama and M. Harada: Limitin, an interferon-like cytokine, transduces inhibitory signals on B-cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx. Exp Hematol, 31(12), 1317-22 (2003) (Pubitemid 37510038)
91. Potla, R., T. Koeck, J. Wegrzyn, S. Cherukuri, K. Shimoda, D. P. Baker, J. Wolfman, S. M. Planchon, C. Esposito, B. Hoit, J. Dulak, A. Wolfman, D. Stuehr and A. C. Larner: Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol, 26(22), 8562-71 (2006) (Pubitemid 44748588)
92. Ishida, N., K. Oritani, M. Shiraga, H. Yoshida, S. Kawamoto, H. Ujiie, H. Masaie, M. Ichii, Y. Tomiyama and Y. Kanakura: Differential effects of a novel IFNzeta/ limitin and IFN-alpha on signals for Daxx induction and Crk phosphorylation that couple with growth control of megakaryocytes. Exp Hematol, 33(4), 495-503 (2005) (Pubitemid 40387633)
93. Mori, Y., K. Hirose, K. Suzuki, H. Nakajima, Y. Seto, K. Ikeda, K. Shimoda, K. Nakayama, Y. Saito and I. Iwamoto: Tyk2 is essential for IFN-alpha-induced gene expression in mast cells. Int Arch Allergy Immunol, 134 Suppl 1, 25-9 (2004) (Pubitemid 38721123)
94. Budagian, V., E. Bulanova, R. Paus and S. Bulfone-Paus: IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev, 17(4), 259-80 (2006) (Pubitemid 44038618)
95. Masuda, A., T. Matsuguchi, K. Yamaki, T. Hayakawa, M. Kubo, W. J. Larochelle and Y. Yoshikai: Interleukin-15 induces rapid tyrosine phosphorylation of STAT6 and the expression of interleukin-4 in mouse mast cells. J Biol Chem, 275(38), 29331-7 (2000) (Pubitemid 32043804)
96. Vogl, C., T. Flatt, B. Fuhrmann, E. Hofmann, B. Wallner, R. Stiefvater, P. Kovarik, B. Strobl and M. Muller: Transcriptome analysis reveals a major impact of JAK protein tyrosine kinase 2 (Tyk2) on the expression of interferon-responsive and metabolic genes. BMC Genomics, 11, 199 (2010)
97. Radwan, M., I. Miller, T. Grunert, M. Marchetti-Deschmann, C. Vogl, N. O'Donoghue, M. J. Dunn, T. Kolbe, G. Allmaier, M. Gemeiner, M. Muller and B. Strobl: The impact of tyrosine kinase 2 (Tyk2) on the proteome of murine macrophages and their response to lipopolysaccharide (LPS). Proteomics, 8(17), 3469-85 (2008)
98. Karaghiosoff, M., R. Steinborn, P. Kovarik, G. Kriegshauser, M. Baccarini, B. Donabauer, U. Reichart, T. Kolbe, C. Bogdan, T. Leanderson, D. Levy, T. Decker and M. Muller: Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol, 4(5), 471-7 (2003) (Pubitemid 36592440)
99. Taniguchi, T. and A. Takaoka: A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol, 2(5), 378-86 (2001) (Pubitemid 33674050)
100. Gough, D. J., N. L. Messina, L. Hii, J. A. Gould, K. Sabapathy, A. P. Robertson, J. A. Trapani, D. E. Levy, P. J. Hertzog, C. J. Clarke and R. W. Johnstone: Functional crosstalk between type I and II interferon through the regulated expression of STAT1. PLoS Biol, 8(4), e1000361 (2010)
101. Fleetwood, A. J., H. Dinh, A. D. Cook, P. J. Hertzog and J. A. Hamilton: GM-CSF-and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J Leukoc Biol, 86(2), 411-21 (2009)
102. Zurney, J., K. E. Howard and B. Sherry: Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol, 81(24), 13668-80 (2007) (Pubitemid 350247860)
103. Strobl, B., I. Bubic, U. Bruns, R. Steinborn, R. Lajko, T. Kolbe, M. Karaghiosoff, U. Kalinke, S. Jonjic and M. Muller: Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J Immunol, 175(6), 4000-8 (2005) (Pubitemid 41292062)
104. Radwan, M., R. Stiefvater, T. Grunert, O. Sharif, I. Miller, M. Marchetti-Deschmann, G. Allmaier, M. Gemeiner, S. Knapp, P. Kovarik, M. Muller and B. Strobl: Tyrosine kinase 2 controls IL-1beta production at the translational level. J Immunol, 185(6), 3544-53 (2010)
105. Friedman, R. M., R. M. Esteban, D. H. Metz, D. R. Tovell, I. M. Kerr and R. Williamson: Translation of RNA by L cell extracts: Effect of interferon. FEBS Lett, 24(3), 273-277 (1972)
106. Metz, D. H. and M. Esteban: Interferon inhibits viral protein synthesis in L cells infected with vaccinia virus. Nature, 238(5364), 385-8 (1972)
107. Kerr, I. M., R. M. Friedman, R. E. Brown, L. A. Ball and J. C. Brown: Inhibition of Protein Synthesis in Cell-Free Systems from Interferon-Treated, Infected Cells: Further Characterization and Effect of FormylmethionyltRNA( F). J Virol, 13(1), 9-21 (1974)
108. Kaur, S., E. Katsoulidis and L. C. Platanias: Akt and mRNA translation by interferons. Cell Cycle, 7(14), 2112-6 (2008) (Pubitemid 352031512)
109. Belladonna, M. L., J. C. Renauld, R. Bianchi, C. Vacca, F. Fallarino, C. Orabona, M. C. Fioretti, U. Grohmann and P. Puccetti: IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol, 168(11), 5448-54 (2002) (Pubitemid 34556122)
110. Weaver, C. T., L. E. Harrington, P. R. Mangan, M. Gavrieli and K. M. Murphy: Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity, 24(6), 677-88 (2006) (Pubitemid 43867371)
111. Stoiber, D., B. Kovacic, C. Schuster, C. Schellack, M. Karaghiosoff, R. Kreibich, E. Weisz, M. Artwohl, O. C. Kleine, M. Muller, S. Baumgartner-Parzer, J. Ghysdael, M. Freissmuth and V. Sexl: TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest, 114(11), 1650-8 (2004) (Pubitemid 40385556)
112. Simma, O., E. Zebedin, N. Neugebauer, C. Schellack, A. Pilz, S. Chang-Rodriguez, K. Lingnau, E. Weisz, E. M. Putz, W. F. Pickl, T. Felzmann, M. Muller, T. Decker, V. Sexl and D. Stoiber: Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res, 69(1), 203-11 (2009)
113. Nguyen, K. B., W. T. Watford, R. Salomon, S. R. Hofmann, G. C. Pien, A. Morinobu, M. Gadina, J. J. O'Shea and C. A. Biron: Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science, 297(5589), 2063-6 (2002)
114. Freudenberg, M. A., T. Merlin, C. Kalis, Y. Chvatchko, H. Stubig and C. Galanos: Cutting edge: a murine, IL-12-independent pathway of IFN-gamma induction by gramnegative bacteria based on STAT4 activation by Type I IFN and IL-18 signaling. J Immunol, 169(4), 1665-8 (2002) (Pubitemid 34857622)
115. Meeks, K. D., A. N. Sieve, J. K. Kolls, N. Ghilardi and R. E. Berg: IL-23 is required for protection against systemic infection with Listeria monocytogenes. J Immunol, 183(12), 8026-34 (2009)
116. Cooper, A. M. IL-23 and IL-17 have a multi-faceted largely negative role in fungal infection. Eur J Immunol, 37(10), 2680-2 (2007) (Pubitemid 47578287)
117. Kohyama, S., S. Ohno, A. Isoda, O. Moriya, M. L. Belladonna, H. Hayashi, Y. Iwakura, T. Yoshimoto, T. Akatsuka and M. Matsui: IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17. J Immunol, 179(6), 3917-25 (2007)
118. Muller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel and M. Aguet: Functional role of type I and type II interferons in antiviral defense. Science, 264(5167), 1918-21 (1994) (Pubitemid 24245635)
119. Decker, T., M. Muller and S. Stockinger: The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol, 5(9), 675-87 (2005) (Pubitemid 43086170)
120. Auerbuch, V., D. G. Brockstedt, N. Meyer-Morse, M. O'Riordan and D. A. Portnoy: Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med, 200(4), 527-33 (2004) (Pubitemid 39121909)
121. Carrero, J. A., B. Calderon and E. R. Unanue: Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med, 200(4), 535-40 (2004) (Pubitemid 39121910)
122. Aizu, K., W. Li, T. Yajima, T. Arai, K. Shimoda, Y. Nimura and Y. Yoshikai: An important role of Tyk2 in APC function of dendritic cells for priming CD8+ T cells producing IFN-gamma. Eur J Immunol, 36(11), 3060-70 (2006) (Pubitemid 44782578)
123. Li, W., H. Yamada, T. Yajima, R. Nakagawa, K. Shimoda, K. Nakayama and Y. Yoshikai: Tyk2 signaling in host environment plays an important role in contraction of antigen-specific CD8+ T cells following a microbial infection. J Immunol, 178(7), 4482-8 (2007) (Pubitemid 46492400)
124. Yap, G. S., R. Ortmann, E. Shevach and A. Sher: A heritable defect in IL-12 signaling in B10.Q/J mice. II. Effect on acute resistance to Toxoplasma gondii and rescue by IL-18 treatment. J Immunol, 166(9), 5720-5 (2001) (Pubitemid 32374197)
125. Kamezaki, K., K. Shimoda, A. Numata, T. Matsuda, K. Nakayama and M. Harada: The role of Tyk2, Stat1 and Stat4 in LPS-induced endotoxin signals. Int Immunol, 16(8), 1173-9 (2004) (Pubitemid 39136734)
126. Car, B. D., V. M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet and B. Ryffel: Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med, 179(5), 1437-44 (1994) (Pubitemid 24129561)
127. Painz, R., I. Walter, T. Kolbe, D. Rigler, C. Vogl, R. Steinborn, T. Rulicke, M. Helmreich, M. Karaghiosoff and M. Muller: Organ-specific and differential requirement of TYK2 and IFNAR1 for LPS-induced iNOS expression in vivo. Immunobiology, 212(9-10), 863-75 (2007) (Pubitemid 350246254)
128. Schneider, A., U. Reichart, W. Gerner, T. Kolbe, A. Saalmuller and M. Muller: Selective contribution of Tyk2 to cell activation by lipopolysaccharide. FEBS Lett, 582(25-26), 3681-6 (2008)
129. Costantino, G., M. Egerbacher, T. Kolbe, M. Karaghiosoff, B. Strobl, C. Vogl, M. Helmreich and M. Muller: Tyk2 and signal transducer and activator of transcription 1 contribute to intestinal I/R injury. Shock, 29(2), 238-44 (2008)
130. Spach, K. M., R. Noubade, B. Mcelvany, W. F. Hickey, E. P. Blankenhorn and C. Teuscher: A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis. J Immunol, 182(12), 7776-83 (2009)
131. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. Mcclanahan, R. A. Kastelein and D. J. Cua: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med, 201(2), 233-40 (2005) (Pubitemid 40189432)
132. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. Mcclanahan, R. A. Kastelein, J. D. Sedgwick and D. J. Cua: Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med, 198(12), 1951-7 (2003) (Pubitemid 38032126)
133. Thakker, P., M. W. Leach, W. Kuang, S. E. Benoit, J. P. Leonard and S. Marusic: IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol, 178(4), 2589-98 (2007) (Pubitemid 46233462)
134. Harrington, L. E., R. D. Hatton, P. R. Mangan, H. Turner, T. L. Murphy, K. M. Murphy and C. T. Weaver: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6(11), 1123-32 (2005) (Pubitemid 41541790)
135. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian and C. Dong: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6(11), 1133-41 (2005) (Pubitemid 41541791)
136. Komiyama, Y., S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo and Y. Iwakura: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol, 177(1), 566-73 (2006) (Pubitemid 43939170)
137. Okuda, Y., S. Sakoda, C. C. Bernard, H. Fujimura, Y. Saeki, T. Kishimoto and T. Yanagihara: IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int Immunol, 10(5), 703-8 (1998) (Pubitemid 28221471)
138. Eugster, H. P., K. Frei, M. Kopf, H. Lassmann and A. Fontana: IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol, 28(7), 2178-87 (1998) (Pubitemid 28321302)
139. Samoilova, E. B., J. L. Horton, B. Hilliard, T. S. Liu and Y. Chen: IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol, 161(12), 6480-6 (1998) (Pubitemid 28562184)
140. Serada, S., M. Fujimoto, M. Mihara, N. Koike, Y. Ohsugi, S. Nomura, H. Yoshida, T. Nishikawa, F. Terabe, T. Ohkawara, T. Takahashi, B. Ripley, A. Kimura, T. Kishimoto and T. Naka: IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A, 105(26), 9041-6 (2008)
141. Ferber, I. A., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. Dalton and C. G. Fathman: Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol, 156(1), 5-7 (1996)
142. Krakowski, M. and T. Owens: Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol, 26(7), 1641-6 (1996) (Pubitemid 26230015)
143. Owens, T., H. Wekerle and J. Antel: Genetic models for CNS inflammation. Nat Med, 7(2), 161-6 (2001) (Pubitemid 32148481)
144. Seto, Y., H. Nakajima, A. Suto, K. Shimoda, Y. Saito, K. I. Nakayama and I. Iwamoto: Enhanced Th2 cellmediated allergic inflammation in Tyk2-deficient mice. J Immunol, 170(2), 1077-83 (2003) (Pubitemid 36070564)
145. Kasaian, M. T. and D. K. Miller: IL-13 as a therapeutic target for respiratory disease. Biochem Pharmacol, 76(2), 147-55 (2008)
146. Hosogi, M., H. Tonogaito, A. Aioi, K. Hamada, K. Shimoda, R. Muromoto, T. Matsuda and Y. Miyachi: Hapten-induced contact hypersensitivity is enhanced in Tyk2-deficient mice. J Dermatol Sci, 36(1), 51-6 (2004) (Pubitemid 39370025)
147. Wang, B., C. Esche, A. Mamelak, I. Freed, H. Watanabe and D. N. Sauder: Cytokine knockouts in contact hypersensitivity research. Cytokine Growth Factor Rev, 14(5), 381-9 (2003) (Pubitemid 37099452)
148. Wakita, D., K. Chamoto, Y. Zhang, Y. Narita, D. Noguchi, H. Ohnishi, T. Iguchi, T. Sakai, H. Ikeda and T. Nishimura: An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int Immunol, 18(3), 425-34 (2006) (Pubitemid 43329604)
149. Nakajima, H., F. Shibata, H. Kumagai, K. Shimoda and T. Kitamura: Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3. Int J Hematol, 84(1), 54-9 (2006) (Pubitemid 44756777)
150. Ide, H., T. Nakagawa, Y. Terado, Y. Kamiyama, S. Muto and S. Horie: Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochem Biophys Res Commun, 369(2), 292-6 (2008) (Pubitemid 351400466)
151. Schuster, C., M. Muller, M. Freissmuth, V. Sexl and D. Stoiber: Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells". Biochem Biophys Res Commun, 366(4), 869-70 (2008)
152. Mellado, M., J. M. Rodriguez-Frade, S. Manes and A. C. Martinez: Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol, 19, 397-421 (2001) (Pubitemid 32368041)
153. Muller, A., B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. Mcclanahan, E. Murphy, W. Yuan, S. N. Wagner, J. L. Barrera, A. Mohar, E. Verastegui and A. Zlotnik: Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50-6 (2001) (Pubitemid 32225831)
154. Wiley, H. E., E. B. Gonzalez, W. Maki, M. T. Wu and S. T. Hwang: Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst, 93(21), 1638-43 (2001) (Pubitemid 33094871)
155. Minegishi, Y., M. Saito, T. Morio, K. Watanabe, K. Agematsu, S. Tsuchiya, H. Takada, T. Hara, N. Kawamura, T. Ariga, H. Kaneko, N. Kondo, I. Tsuge, A. Yachie, Y. Sakiyama, T. Iwata, F. Bessho, T. Ohishi, K. Joh, K. Imai, K. Kogawa, M. Shinohara, M. Fujieda, H. Wakiguchi, S. Pasic, M. Abinun, H. D. Ochs, E. D. Renner, A. Jansson, B. H. Belohradsky, A. Metin, N. Shimizu, S. Mizutani, T. Miyawaki, S. Nonoyama and H. Karasuyama: Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity, 25(5), 745-55 (2006) (Pubitemid 46131400)
156. Song, X. C., G. Fu, X. Yang, Z. Jiang, Y. Wang and G. W. Zhou: Protein expression profiling of breast cancer cells by dissociable antibody microarray (DAMA) staining. Mol Cell Proteomics, 7(1), 163-9 (2008) (Pubitemid 351248241)
157. Zhu, X., J. Lv, L. Yu, J. Wu, S. Zou and S. Jiang: Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol, 112(1), 248-56 (2009)
158. Caldas-Lopes, E., L. Cerchietti, J. H. Ahn, C. C. Clement, A. I. Robles, A. Rodina, K. Moulick, T. Taldone, A. Gozman, Y. Guo, N. Wu, E. De Stanchina, J. White, S. S. Gross, Y. Ma, L. Varticovski, A. Melnick and G. Chiosis: Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A, 106(20), 8368-73 (2009)
159. Kaminker, J. S., Y. Zhang, A. Waugh, P. M. Haverty, B. Peters, D. Sebisanovic, J. Stinson, W. F. Forrest, J. F. Bazan, S. Seshagiri and Z. Zhang: Distinguishing cancerassociated missense mutations from common polymorphisms. Cancer Res, 67(2), 465-73 (2007) (Pubitemid 46192182)
160. Tomasson, M. H., Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. Mclellan, J. E. Payton, P. Westervelt, J. F. Dipersio, D. C. Link, M. J. Walter, T. A. Graubert, M. Watson, J. Baty, S. Heath, W. D. Shannon, R. Nagarajan, C. D. Bloomfield, E. R. Mardis, R. K. Wilson and T. J. Ley: Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood, 111(9), 4797-808 (2008)
161. Haan, C., D. C. Kroy, S. Wuller, U. Sommer, T. Nocker, C. Rolvering, I. Behrmann, P. C. Heinrich and S. Haan: An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. J Immunol, 182(5), 2969-77 (2009)
162. Ruhe, J. E., S. Streit, S. Hart, C. H. Wong, K. Specht, P. Knyazev, T. Knyazeva, L. S. Tay, H. L. Loo, P. Foo, W. Wong, S. Pok, S. J. Lim, H. Ong, M. Luo, H. K. Ho, K. Peng, T. C. Lee, M. Bezler, C. Mann, S. Gaertner, H. Hoefler, S. Iacobelli, S. Peter, A. Tay, S. Brenner, B. Venkatesh and A. Ullrich: Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res, 67(23), 11368-76 (2007) (Pubitemid 350248564)
163. Shide, K., K. Shimoda, K. Kamezaki, H. Kakumitsu, T. Kumano, A. Numata, F. Ishikawa, K. Takenaka, K. Yamamoto, T. Matsuda and M. Harada: Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leuk Res, 31(8), 1077-84 (2007)
164. Suarez-Gestal, M., M. Calaza and A. Gonzalez: Lack of interaction between systemic lupus erythematosusassociated polymorphisms in TYK2 and IRF5. J Rheumatol, 37(3), 676-7; author reply 678 (2010)
165. Sigurdsson, S., G. Nordmark, H. H. Goring, K. Lindroos, A. C. Wiman, G. Sturfelt, A. Jonsen, S. Rantapaa-Dahlqvist, B. Moller, J. Kere, S. Koskenmies, E. Widen, M. L. Eloranta, H. Julkunen, H. Kristjansdottir, K. Steinsson, G. Alm, L. Ronnblom and A. C. Syvanen: Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet, 76(3), 528-37 (2005) (Pubitemid 40250533)
166. Hellquist, A., T. M. Jarvinen, S. Koskenmies, M. Zucchelli, C. Orsmark-Pietras, L. Berglind, J. Panelius, T. Hasan, H. Julkunen, M. D'amato, U. Saarialho-Kere and J. Kere: Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus. J Rheumatol, 36(8), 1631-8 (2009)
167. Jarvinen, T. M., A. Hellquist, S. Koskenmies, E. Einarsdottir, L. L. Koskinen, L. Jeskanen, L. Berglind, J. Panelius, T. Hasan, A. Ranki, J. Kere and U. Saarialho-Kere: Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol, 19(2), 123-31 (2010)
168. Cunninghame Graham, D. S., M. Akil and T. J. Vyse: Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology (Oxford), 46(6), 927-30 (2007) (Pubitemid 47062497)
169. Mero, I. L., A. R. Lorentzen, M. Ban, C. Smestad, E. G. Celius, J. H. Aarseth, K. M. Myhr, J. Link, J. Hillert, T. Olsson, I. Kockum, T. Masterman, A. B. Oturai, H. B. Sondergaard, F. Sellebjerg, J. Saarela, A. Kemppinen, I. Elovaara, A. Spurkland, F. Dudbridge, B. A. Lie and H. F. Harbo: A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur J Hum Genet, 18(4), 502-4 (2010)
170. Ban, M., A. Goris, A. R. Lorentzen, A. Baker, T. Mihalova, G. Ingram, D. R. Booth, R. N. Heard, G. J. Stewart, E. Bogaert, B. Dubois, H. F. Harbo, E. G. Celius, A. Spurkland, R. Strange, C. Hawkins, N. P. Robertson, F. Dudbridge, J. Wason, P. L. De Jager, D. Hafler, J. D. Rioux, A. J. Ivinson, J. L. Mccauley, M. Pericak-Vance, J. R. Oksenberg, S. L. Hauser, D. Sexton, J. Haines, S. Sawcer and A. Compston: Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet, 17(10), 1309-13 (2009)
171. Johnson, B. A., J. Wang, E. M. Taylor, S. J. Caillier, J. Herbert, O. A. Khan, A. H. Cross, P. L. De Jager, P. A. Gourraud, B. C. Cree, S. L. Hauser and J. R. Oksenberg: Multiple sclerosis susceptibility alleles in African Americans. Genes Immun, 11(4), 343-50 (2010)
172. Consortium, Australia and New Zealand Multiple Scelrosis Genetics: Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet, 41(7), 824-8 (2009)
173. Sato, K., M. Shiota, S. Fukuda, E. Iwamoto, H. Machida, T. Inamine, S. Kondo, K. Yanagihara, H. Isomoto, Y. Mizuta, S. Kohno and K. Tsukamoto: Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. J Clin Immunol, 29(6), 815-25 (2009)
174. Franke, A., D. P. Mcgovern, J. C. Barrett, K. Wang, G. L. Radford-Smith, T. Ahmad, C. W. Lees, T. Balschun, J. Lee, R. Roberts, C. A. Anderson, J. C. Bis, S. Bumpstead, D. Ellinghaus, E. M. Festen, M. Georges, T. Green, T. Haritunians, L. Jostins, A. Latiano, C. G. Mathew, G. W. Montgomery, N. J. Prescott, S. Raychaudhuri, J. I. Rotter, P. Schumm, Y. Sharma, L. A. Simms, K. D. Taylor, D. Whiteman, C. Wijmenga, R. N. Baldassano, M. Barclay, T. M. Bayless, S. Brand, C. Buning, A. Cohen, J. F. Colombel, M. Cottone, L. Stronati, T. Denson, M. De Vos, R. D'inca, M. Dubinsky, C. Edwards, T. Florin, D. Franchimont, R. Gearry, J. Glas, A. Van Gossum, S. L. Guthery, J. Halfvarson, H. W. Verspaget, J. P. Hugot, A. Karban, D. Laukens, I. Lawrance, M. Lemann, A. Levine, C. Libioulle, E. Louis, C. Mowat, W. Newman, J. Panes, A. Phillips, D. D. Proctor, M. Regueiro, R. Russell, P. Rutgeerts, J. Sanderson, M. Sans, F. Seibold, A. H. Steinhart, P. C. Stokkers, L. Torkvist, G. Kullak-Ublick, D. Wilson, T. Walters, S. R. Targan, S. R. Brant, J. D. Rioux, M. D'amato, R. K. Weersma, S. Kugathasan, A. M. Griffiths, J. C. Mansfield, S. Vermeire, R. H. Duerr, M. S. Silverberg, J. Satsangi, S. Schreiber, J. H. Cho, V. Annese, H. Hakonarson, M. J. Daly and M. Parkes: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010)
175. Strange, A., F. Capon, C. C. Spencer, J. Knight, M. E. Weale, M. H. Allen, A. Barton, G. Band, C. Bellenguez, J. G. Bergboer, J. M. Blackwell, E. Bramon, S. J. Bumpstead, J. P. Casas, M. J. Cork, A. Corvin, P. Deloukas, A. Dilthey, A. Duncanson, S. Edkins, X. Estivill, O. Fitzgerald, C. Freeman, E. Giardina, E. Gray, A. Hofer, U. Huffmeier, S. E. Hunt, A. D. Irvine, J. Jankowski, B. Kirby, C. Langford, J. Lascorz, J. Leman, S. Leslie, L. Mallbris, H. S. Markus, C. G. Mathew, W. H. Mclean, R. Mcmanus, R. Mossner, L. Moutsianas, A. T. Naluai, F. O. Nestle, G. Novelli, A. Onoufriadis, C. N. Palmer, C. Perricone, M. Pirinen, R. Plomin, S. C. Potter, R. M. Pujol, A. Rautanen, E. Riveira-Munoz, A. W. Ryan, W. Salmhofer, L. Samuelsson, S. J. Sawcer, J. Schalkwijk, C. H. Smith, M. Stahle, Z. Su, R. Tazi-Ahnini, H. Traupe, A. C. Viswanathan, R. B. Warren, W. Weger, K. Wolk, N. Wood, J. Worthington, H. S. Young, P. L. Zeeuwen, A. Hayday, A. D. Burden, C. E. Griffiths, J. Kere, A. Reis, G. Mcvean, D. M. Evans, M. A. Brown, J. N. Barker, L. Peltonen, P. Donnelly and R. C. Trembath: A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet, 42(11), 985-90 (2010)
176. Wallace, C., D. J. Smyth, M. Maisuria-Armer, N. M. Walker, J. A. Todd and D. G. Clayton: The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat Genet, 42(1), 68-71 (2010)
177. Tao, J. H., Y. F. Zou, X. L. Feng, J. Li, F. Wang, F. M. Pan and D. Q. Ye: Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases. Mol Biol Rep (2010)
178. Malerich, J. P., J. S. Lam, B. Hart, R. M. Fine, B. Klebansky, M. J. Tanga and A. D'andrea: Diamino-1, 2, 4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3. Bioorg Med Chem Lett, 20(24), 7454-7 (2010)
179. Tsui, V., P. Gibbons, M. Ultsch, K. Mortara, C. Chang, W. Blair, R. Pulk, M. Stanley, M. Starovasnik, D. Williams, M. Lamers, P. Leonard, S. Magnuson, J. Liang and C. Eigenbrot: A new regulatory switch in a JAK protein kinase. Proteins (2010)
180. Dawson, M. A., A. J. Bannister, B. Gottgens, S. D. Foster, T. Bartke, A. R. Green and T. Kouzarides: JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature, 461(7265), 819-22 (2009)